- Home
- VLGEA vs EYPT Comparison
VLGEA vs EYPT Comparison
Compare VLGEA & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLGEA
- EYPT
- Stock Information
- Founded
- VLGEA 1937
- EYPT 1987
- Country
- VLGEA United States
- EYPT United States
- Employees
- VLGEA N/A
- EYPT N/A
- Industry
- VLGEA Food Chains
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- VLGEA Consumer Staples
- EYPT Industrials
- Exchange
- VLGEA Nasdaq
- EYPT Nasdaq
- Market Cap
- VLGEA 501.1M
- EYPT 489.4M
- IPO Year
- VLGEA N/A
- EYPT 2005
- Fundamental
- Price
- VLGEA $31.79
- EYPT $6.15
- Analyst Decision
- VLGEA
- EYPT Strong Buy
- Analyst Count
- VLGEA 0
- EYPT 8
- Target Price
- VLGEA N/A
- EYPT $25.71
- AVG Volume (30 Days)
- VLGEA 19.8K
- EYPT 869.2K
- Earning Date
- VLGEA 03-04-2025
- EYPT 03-06-2025
- Dividend Yield
- VLGEA 3.13%
- EYPT N/A
- EPS Growth
- VLGEA 2.47
- EYPT N/A
- EPS
- VLGEA 3.48
- EYPT N/A
- Revenue
- VLGEA $2,257,909,000.00
- EYPT $45,713,000.00
- Revenue This Year
- VLGEA N/A
- EYPT N/A
- Revenue Next Year
- VLGEA N/A
- EYPT N/A
- P/E Ratio
- VLGEA $9.26
- EYPT N/A
- Revenue Growth
- VLGEA 3.42
- EYPT 7.50
- 52 Week Low
- VLGEA $24.57
- EYPT $5.90
- 52 Week High
- VLGEA $35.34
- EYPT $29.31
- Technical
- Relative Strength Index (RSI)
- VLGEA 37.06
- EYPT 36.22
- Support Level
- VLGEA $33.90
- EYPT $5.90
- Resistance Level
- VLGEA $34.83
- EYPT $6.67
- Average True Range (ATR)
- VLGEA 0.76
- EYPT 0.71
- MACD
- VLGEA -0.35
- EYPT -0.04
- Stochastic Oscillator
- VLGEA 10.35
- EYPT 8.99
About VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.